EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Advances in the clinical management of high‐risk Wilms tumors

Michael V Ortiz iD, Christa Koenig iD, Amy E Armstrong iD, Jesper Brok, Beatriz de Camargo iD, Annelies M C Mavinkurve-Groothuis iD, Thelma B Velasquez Herrera, Rajkumar Venkatramani, Andrew D Woods iD, Jeffrey S Dome iD, Filippo Spreafico iD

Pediatric Blood & Cancer · 2023

DOI: 10.1002/pbc.30153 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pediatric Blood & Cancer, 2023. Verfasst von Michael V Ortiz und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Kidney Neoplasms, Wilms Tumor. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 83 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Outcomes are excellent for the majority of patients with Wilms tumors (WT). However, there remain WT subgroups for which the survival rate is approximately 50% or lower. Acknowledging that the composition of this high‐risk group has changed over time reflecting improvements in therapy, we introduce the authors’ view of the historical and current approach to the classification and treatment of high‐risk WT. For this review, we consider high‐risk WT to include patients with newly diagnosed metastatic blastemal‐type or diffuse anaplastic histology, those who relapse after having been initially treated with three or more different chemotherapeutics, or those who relapse more than once. In certain low‐ or low middle‐income settings, socio‐economic factors expand the definition of what constitutes a high‐risk WT. As conventional therapies are inadequate to cure the majority of high‐risk WT patients, advancement of laboratory and early‐phase clinical investigations to identify active agents is urgently needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney NeoplasmsWilms TumorHumansNeoplasm StagingPrognosisRecurrence

Stichwörter der Autor:innen

COGSIOPWilms tumorhigh risknephroblastomarelapsed

Autor:innen und Institutionen

  • Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Division of Pediatric Hematology and Oncology, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Division of Pediatric Hematology/Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Developmental Biology and Cancer Research and Teaching Department, University College London Great Ormond Street Institute of Child Health, London, UK.
  • Department of Pediatric Oncology and Hematology, Rigshospitalet, Copenhagen, Denmark.
  • Pediatric Hematology and Oncology Program, Research Center, Instituto Nacional de Cancer, Rio de Janeiro, Brazil.

ORCID-Profile: Michael V Ortiz, Christa Koenig, Amy E Armstrong, Beatriz de Camargo, Annelies M C Mavinkurve-Groothuis, Andrew D Woods, Jeffrey S Dome, Filippo Spreafico

Förderung

  • NCI NIH HHS

Zitieren

APA

Ortiz, M. V., Koenig, C., Armstrong, A. E., Brok, J., de Camargo, B., Mavinkurve-Groothuis, A. M. C., Herrera, T. B. V., Venkatramani, R., Woods, A. D., Dome, J. S., & Spreafico, F. (2023). Advances in the clinical management of high‐risk Wilms tumors. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30153

Vancouver

Ortiz MV, Koenig C, Armstrong AE, Brok J, de Camargo B, Mavinkurve-Groothuis AMC, et al. Advances in the clinical management of high‐risk Wilms tumors. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30153

BibTeX
@article{Ortiz2023,
  author = {Ortiz, Michael V and Koenig, Christa and Armstrong, Amy E and Brok, Jesper and de Camargo, Beatriz and Mavinkurve-Groothuis, Annelies M C and Herrera, Thelma B Velasquez and Venkatramani, Rajkumar and Woods, Andrew D and Dome, Jeffrey S and Spreafico, Filippo},
  title = {Advances in the clinical management of high‐risk Wilms tumors},
  journal = {Pediatric Blood & Cancer},
  year = {2023},
  doi = {10.1002/pbc.30153}
}
Kostenlos starten →